Mar 02,2023 TOP STORY

Kaia Health Becomes World's Most Broadly Covered Back Pain Offering After Gaining Approval for Prescription in Germany

Kaia Back Pain, a digital therapy for the treatment of non-specific back pain has been permanently added to the Directory of Digital Health Applications (DiGA) by the German Federal Institute for Drugs and Medical Devices (BfArM), adding to the Kaia COPD DiGA listing in December. The digital therapy is available free of charge to Germans with statutory health insurance when prescribed.

PRODUCT

#reimbursement

#pdt

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 16,2023

Kaia Health Now World's Most Widely Available Digital COPD Treatment with Approval for Prescription Covering 73 Million People in Germany

Kaia Health today announced that Kaia COPD, a digital application for the treatment of chronic obstructive pulmonary disease (COPD), has been included in the DiGA directory by the German Federal Institute for Drugs and Medical Devices (BfArM) as a digital health application (DiGA) and can now be prescribed by medical providers and will be covered by statutory health insurance.

PRODUCT

#reimbursement

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 10,2023

Hygieia Expands to Arizona, as Endocrinology Associates, PA, Joins d-Nav® Insulin Management Clinical Partnership Program

Hygieia, a provider of digital therapeutics for insulin management, has added Endocrinology Associates, PA, in Scottsdale and Chandler, AZ, as a clinical partner. This makes Hygieia’s d-Nav® autonomous insulin therapy service available to patients with type 2 diabetes in Arizona. Partnership model gives physicians better tools for insulin therapy and offers new reimbursement opportunities

COLLABORATION PARTNERSHIP

#institution

#software

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Jan 10,2023

Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics

COEUS’ COEBRA™ Platform facilitates value and outcomes based agreements for government and commercial payers. As Pear continues to engage in clinical and contractual conversations with state Medicaid programs, its agreement with COEUS makes it easier for individual states to engage in value-based contracting to access Pear’s PDTs.

COLLABORATION PARTNERSHIP

#product & service

#reimbursement

#pdt

View Analyst & Ambassador Comments
Go to original news
Jan 18,2023

Pear Therapeutics' PDTs added to Florida Medicaid Preferred Drug List

Pear Therapeutics' reSET and reSET-O prescription digital therapeutics are available to Florida's five million Medicaid patients via its Preferred Drug List as of this month. Patients can access Pear's reSET for substance use disorder and reSET-O for opioid use disorder. Over the past months, the company has closed contracts with the Wisconsin Department of Health Services to offer its reSET and reSET-O prescription digital therapeutics, and expanded the partnership with Spero Health.

PRODUCT

#reimbursement

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 06,2023

MyndVR announces first-ever payer partnership, expanding VR therapy to seniors in New York

MyndVR, a therapeutic VR company focused on seniors, is now covered by insurance for the first time through a managed care organization in New York. The company’s VR content has been available to AgeWell’s Carewell members since the start of this year. CareWell plan members can use MyndVR headsets to enjoy virtual travel, special adventures and entertainment. They can also share their experiences in real time with relatives using VR. MyndVR hopes to continue expanding coverage among Medicare Advantage and Managed Medicaid plans.

COLLABORATION PARTNERSHIP

#insurance

#virtual reality

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Dec 06,2022

Digital Therapeutics Alliance and Curebase release publication setting the stage for a fit-for-purpose evidence standard for digital therapeutics (DTx)

The Digital Therapeutics Alliance (DTA), a global non-profit trade association with the mission of broadening the understanding, adoption, and integration of digital therapeutics into healthcare, in collaboration with DTA Resource Partner, Curebase, a company committed to democratizing access to clinical studies, today released a publication to provide a fit-for-purpose evidence standard for DTx product regulatory, reimbursement, and clinical acceptance.

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Dec 15,2022

Rx.Health and Wise Therapeutics collaborate to provide game-based digital therapeutic to anxiety patients

Rx.Health, the leading evidence-based automated care coordination platform, has announced a partnership with Wise Therapeutics, a leading provider of game-based digital therapeutics for mental health. This partnership will enable Rx.Health's health plan and health system users to deploy Wise's mobile game to their patient populations as an integrated digital therapeutic for anxiety.

COLLABORATION PARTNERSHIP

#product & service

#pdt

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Dec 19,2022

Advancing Access to Digital Therapeutics

While the DTx market has gained significant momentum over the last half-decade, DTx developers continue to face challenges, particularly related to coverage, payer acceptance and provider use. The existing barriers have prevented more widespread adoption of products – particularly prescription digital therapeutics (PDTs), which are FDA-cleared software-based treatments required to be prescribed by clinicians. “Insurance coverage is absolutely critical,” Ben Lewis, co-founder and CEO of Limbix, a digital therapeutics solution for adolescent mental health, told Fierce Healthcare in October.

#reimbursement

#pdt

View Analyst & Ambassador Comments
Go to original news
Dec 20,2022

HelloBetter Sleep: First online therapy programme for organic and nonorganic insomnia available on prescription in Germany

HelloBetter Sleep has secured approval as HelloBetter’s sixth DiGA (prescription digital therapeutic) by the German Federal Institute for Drugs and Medical Devices (BfArM) and is now included in the DiGA directory. HelloBetter Sleep is the only prescription digital therapeutic that is approved not just for the treatment of nonorganic insomnia (ICD-10 F51.0), but also organic insomnia (ICD-10 G47.0) in Germany. All statutory as well as many private health insurers will cover the costs of HelloBetter Sleep in full, making it available free of charge to 73 million people in Germany. Over the last 14 months, HelloBetter has managed to secure six regulatory DiGA approvals – more than any other company.

PRODUCT

#reimbursement

#cbt

View Analyst & Ambassador Comments
Go to original news
Subscribe to REIMBURSEMENT